Abstract
Introduction/Aims Limb-girdle muscular dystrophy R1 (LGMDR1) calpain 3-related is one of the most common forms of LGMD. It is typically recessively inherited and associated with progressive weakness of proximal limb-girdle muscles. Recently, several families with an autosomal dominant inheritance transmission pattern have been reported (LGMDD4). Camptocormia is a common clinical feature in these patients. In these families, different mutations in CAPN3 have been identified, including in-frame deletions and missense mutations. In particular, two patients presenting with camptocormia carried the p.Lys254del missense mutation without a second identified mutation in CAPN3.
Methods Among our patients, we identified two LGMDR1 families as carriers of the p.Lys254del mutation by DNA sequencing, both in homozygous and compound heterozygous states and clinically analyzed the family members carrying this mutation.
Results Interestingly, these patients did not present the myopathic characteristics described in the so-called dominant patients. No camptocormia or any other severe clinical symptoms were observed.
Discussion Accordingly, we conclude that the p.Lys254del mutation per se cannot be solely responsible for the camptocormia observed in dominant patients. Other additional undisclosed factors might regulate the phenotype associated to a dominant inheritance pattern in CAPN3 mutation carriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI21/00047 and co-funded by the European Union, and it was, in part, supported by the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED: CB06/05/1126 to A.V., P.C., A.L.d.M. and A.S.), GENE (Association of Neuromuscular diseases of Gipuzkoa) and Fundacion la Caixa (Accion Social).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Comision de Investigacion del Hospital Universitario Infanta Sofia (Madrid) and Comite de Etica del Area Sanitaria de Lugo, A Marina y Monforte (Lugo); ethical approval was given and all subjects provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- LGMDR1
- Limb-girdle muscular dystrophy recessive 1-calpain 3 related
- LGMDD4
- Limb-girdle muscular dystrophy dominant 4-calpain 3 related
- MRI
- Magnetic Resonance Image
- OSAHS
- Obstructive sleep apnoea hypopnoea syndrome.
